Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Withdrawal signs

The physician prescribes naltrexone (ReVia) 25 mg PO initially. The nurse is to observe the patient carefully and if no withdrawal signs appear, 100 mg PO of the drug is prescribed every other day. On hand is naltrexone 50-mg tablets. The nurse administers as the initial dose. [Pg.184]

An initial examination of the extent to which lithium may prevent cannabis withdrawal in rats was conducted by Cui et al. (2001), who reported that, at clinically relevant serum levels, lithium prevented the appearance of the cannabis withdrawal syndrome. The authors also noted that these effects were accompanied by a release of oxytocin, which they conclude is responsible for suppression of the withdrawal signs. [Pg.172]

Another pharmacological approach is to reduce the intensity of the symptoms with the o2 adrenergic antagonist clonidine, which is normally used to treat hypertension. Overactivity of the locus coeruleus is associated with opioid withdrawal signs such as tachycardia, nausea, vomiting, and sweating. [Pg.313]

Abrupt cessation of exposure to most drugs of abuse leads to withdrawal signs and symptoms in humans (American Psychiatric Association 2000) and these can be... [Pg.339]

All of these results are consistent with the hypothesis that the withdrawal severity (numbers of withdrawal signs) reflects chronic overstimnlation of nicotinic cholinergic receptors followed by rednced stimnlation. [Pg.412]

The availability of rodent models of nicotine physical dependence and abstinence has made it possible to identify several anatomical regions that play a critical role in these phenomena. In reviewing the evidence, the multidimensional nature of the nicotine withdrawal syndrome should be considered, raising the possibility that different withdrawal signs and symptoms might be attributable to events in different anatomical regions. Table 2 summarizes a number of representative studies. There is some overlap with Table 3 on neurochemical mechanisms, since many studies cited there are studies of regional neurochemistry. [Pg.413]

Catania MA, Firenzuoli F, Crupi A, Mannucd C, Caputi AP, Calapai G (2003) Hypericum perforatum attenuates nicotine withdrawal signs in mice. Psychopharmacology 169 186-189 Cheeta S, Irvine EE, Kenny PJ, File SE (2001) The dorsal raphd nucleus is a crucial structure mediating nicotine s anxiolytic effects and the development of tolerance and withdrawal responses. Psychopharmacology 155 78-85... [Pg.428]

Morphine antagonists and partial agonists. The effects of opioids can be abolished by the antagonists naloxone or naltrexone (A), irrespective of the receptor type involved. Given by itself, neither has any effect in normal subjects however, in opioid-dependent subjects, both precipitate acute withdrawal signs. Because of its rapid presystemic elimination, naloxone is only suitable for parenteral use. Naltrexone is metabolically more stable and is given orally. Naloxone is effective as antidote in the treatment of opioid-induced respiratory paralysis. Since it is more rapidly eliminated than most opioids, repeated doses may be needed. Naltrexone may be used as an adjunct in withdrawal therapy. [Pg.214]

Initiate treatment carefully, with an initial dose of 25 mg of naltrexone. If no withdrawal signs occur, start the patient on 50 mg/day thereafter. [Pg.387]

Drug abuse and dependence There have been no published reports of withdrawal signs or other signs of abuse. The risk of dependence is increased in patients with a history of alcoholism, drug abuse, or in patients with marked personality disorders. [Pg.973]

Drug abuse and dependence Sedative/hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. These reported symptoms range from mild dysphoria and insomnia to a withdrawal syndrome that may include abdominal and muscle cramps, vomiting, sweating, tremors, and convulsions. Zolpidem does not reveal any clear evidence for withdrawal syndrome. [Pg.1181]

A derivative of methadone, L-a-acetyl-methadol (LAAM) has been approved for the treatment of opioid addiction. In some addicts whose degree of tolerance is not known, the patient is first given methadone to stabilize the withdrawal signs and is then switched to LAAM. LAAM has an advantage over methadone in that it has a longer duration of action. Dosing is required only three times per week in most addicts to prevent withdrawal. [Pg.320]

Babies bom to opioid-addicted women also exhibit withdrawal signs, but because of the slower metabolism of opioids in the newborn, the withdrawal signs are more protracted. The babies are often treated with the opium preparation paregoric to reduce withdrawal signs. [Pg.320]

The use of opium dates to 4,000 b.c. At that time it was used for medicinal and recreational purposes mainly via inhalation. Today few opium-containing preparations are used, since the activity of opium is largely attributed to its morphine content. The preparations in use today are those that have constipative effects useful for the treatment of diarrhea. Preparations include pantopon, an injectable hydrochloride of opium alkaloids, and paregoric, a camphorated tincture of opium. Paregoric can be used to treat infants with opioid withdrawal signs following in utero exposure to opioids. [Pg.324]


See other pages where Withdrawal signs is mentioned: [Pg.444]    [Pg.444]    [Pg.146]    [Pg.83]    [Pg.168]    [Pg.169]    [Pg.169]    [Pg.530]    [Pg.535]    [Pg.47]    [Pg.135]    [Pg.418]    [Pg.223]    [Pg.348]    [Pg.349]    [Pg.350]    [Pg.350]    [Pg.351]    [Pg.356]    [Pg.402]    [Pg.405]    [Pg.405]    [Pg.406]    [Pg.406]    [Pg.406]    [Pg.417]    [Pg.417]    [Pg.418]    [Pg.419]    [Pg.420]    [Pg.420]    [Pg.425]    [Pg.426]    [Pg.433]    [Pg.210]    [Pg.320]    [Pg.324]   
See also in sourсe #XX -- [ Pg.402 , Pg.405 , Pg.406 , Pg.412 , Pg.413 , Pg.417 , Pg.420 , Pg.425 , Pg.426 ]




SEARCH



© 2024 chempedia.info